Valuation: Omeros Corporation

Market Cap 136.81Cr 122.05Cr 113.71Cr 103.48Cr 194.87Cr 13TCr 196.31Cr 1.37TCr 534.56Cr 6.72TCr 513.6Cr 502.52Cr 22TCr P/E 2026 *
20.8x
P/E 2027 * 17.9x
Enterprise Value 136.81Cr 122.05Cr 113.71Cr 103.48Cr 194.87Cr 13TCr 196.31Cr 1.37TCr 534.56Cr 6.72TCr 513.6Cr 502.52Cr 22TCr EV / Sales 2026 *
10.7x
EV / Sales 2027 * 6.18x
Free-Float
95.92%
Yield 2026 *
-
Yield 2027 * -
1 day+1.56%
1 week-2.73%
Current month-0.74%
1 month-0.26%
3 months+103.66%
6 months+73.39%
Current year+10.04%
1 week 18.22
Extreme 18.215
19.4
1 month 16.5
Extreme 16.5001
21.24
Current year 6.7
Extreme 6.7023
21.24
1 year 4.06
Extreme 4.055
21.24
3 years 0.92
Extreme 0.92
21.24
5 years 0.92
Extreme 0.92
21.24
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 16/06/1994
Director of Finance/CFO 62 30/06/2024
Chief Tech/Sci/R&D Officer 70 01/11/2019
Director TitleAgeSince
Chairman 67 16/06/1994
Director/Board Member 86 01/01/1995
Director/Board Member 72 01/01/1995
Date Insider Type Main position Quantity % Market Cap. Importance
23/09/26 Exercice

Chief Financial Officer

30,000 0.0414%
31/08/26 Exercice

General Counsel

75,000 0.1036%
27/08/26 Exercice

Director

30,000 0.0415%
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%-2.73%+312.66%+587.27% 134.71Cr
+4.16%+3.42%+49.37%+94.17% 7.42TCr
-0.37%-3.81%+19.75%+78.12% 5.74TCr
+1.63%-1.61%+3.83%+36.89% 4.76TCr
+0.50%+2.94%+344.62%+722.17% 4.43TCr
+3.05%-1.80%+28.78%+34.51% 4.25TCr
+1.00%-1.46%+5.17%+111.90% 4.07TCr
-0.54%+2.41%+9.31%+58.85% 3.1TCr
+4.15%+7.85%+37.38%+32.04% 2.85TCr
+0.76%-1.45%-7.44%-11.12% 2.43TCr
Average +1.59%-0.40%+80.34%+174.48% 3.92TCr
Weighted average by Cap. +1.73%-0.41%+59.38%+139.05%

Financials

2026 *2027 *
Net sales 13Cr 11Cr 11Cr 9.64Cr 18Cr 1.23TCr 18Cr 128.04Cr 50Cr 626.71Cr 48Cr 47Cr 2.01TCr 22Cr 20Cr 18Cr 17Cr 32Cr 2.13TCr 32Cr 222.26Cr 86Cr 1.09TCr 83Cr 81Cr 3.5TCr
Net income 6.5Cr 5.8Cr 5.4Cr 4.91Cr 9.25Cr 625.67Cr 9.32Cr 65Cr 25Cr 319.34Cr 24Cr 24Cr 1.03TCr 8.48Cr 7.57Cr 7.05Cr 6.41Cr 12Cr 816.68Cr 12Cr 85Cr 33Cr 416.82Cr 32Cr 31Cr 1.34TCr
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
05/26/05 $18.90 +1.56% 10,68,073
02/26/02 $18.61 +0.76% 9,56,392
01/26/01 $18.47 -2.99% 12,36,859
30/26/30 $19.04 -1.09% 13,65,766
29/26/29 $19.25 -0.93% 8,41,846
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
18.90USD
Average target price
27.50USD
Spread / Average Target
+45.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock